Rosa Therapeutics IncMonte Rosa Therapeutics Inc, founded in Basel in 2018, can look forward to an upfront payment of US$120m for its second collaboration and licensing deal with Novartis AG to develop protein degraders. A total of US$5.7bn is on the table for the new development of an anti-inflammatory candidate that is not part of Monte Rosa’s pipeline.
Tag Archive for: inflammation
Bild von frimufilms auf FreepikHelsinki-based Aplagon has secured €7m in financing to advance its therapeutic APAC into Phase 2a clinical trials.
Wilfried Le Goff (INSERM, Sorbonne Université)Researchers at Sorbonne Paris have discovered that a membrane protein in adipocytes of obese mice and humans changes the lipid composition of adipose tissue macrophages rendering them more inflammatory and reducing insulin resistance.
British drug discovery specialist BenevolentAI Ltd has licenced its end-to-end AI platform capabilities to Merck KGaA to deliver novel drug candidates for three targets in oncology, neurology and immunology.
Mysthera Therapeutics AG has launched in Basel with $3.5m in seed funding from founding investor Forty51 Ventures. The capital will be used to advance its preclinical portfolio in a variety of autoimmune indications. The focus is on pan-PIM kinase inhibitors that uniquely modulate multilineage immune cell functions.
Tay Therapeutics Ltd announces licencing of its oral BET blocker TayB2 to VYNE Therapeutics Inc as a treatment for immuno-inflammatory and fibrotic disorders.
EpiEndo Pharmaceuticals ehf got the green light for a Phase IIa COPD trial with its non-anbibiotic macrolide EP395